Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$5.89 +7.5%	$7.60	$1.55 ▼ $10.95	$127.28M	2.17	1.33 million shs	9.74 million shs
BHST BioHarvest Sciences	$9.24 +0.3%	$7.50	$4.66 ▼ $9.90	$151.77M	0.68	15,514 shs	6,113 shs
HURA TuHURA Biosciences	$2.98 -0.7%	$2.59	$1.80 ▼ $8.40	$149.15M	0.04	307,359 shs	141,651 shs
OKUR OnKure Therapeutics	$2.73 -0.4%	$2.40	$1.70 ▼ $20.00	$36.88M	0.4	113,586 shs	42,413 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	-10.46%	-8.05%	-25.14%	-17.47%	+87.67%
BHST BioHarvest Sciences	-4.06%	+1.10%	+33.09%	+50.98%	+920,999,900.00%
HURA TuHURA Biosciences	-2.91%	-7.69%	+14.50%	-9.37%	+299,999,900.00%
OKUR OnKure Therapeutics	-2.14%	+37.00%	+17.60%	+21.78%	+273,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.6469 of 5 stars	0.0	4.0	0.0	0.0	3.1	0.0	0.0
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	1.6168 of 5 stars	3.7	0.0	0.0	0.0	2.2	0.0	0.0
OKUR OnKure Therapeutics	3.401 of 5 stars	3.6	0.0	0.0	0.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
BHST BioHarvest Sciences	3.00	Buy	$13.67	47.91% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	325.06% Upside
OKUR OnKure Therapeutics	3.14	Buy	$32.33	1,084.37% Upside

Current Analyst Ratings Breakdown

Latest OKUR, BHST, HURA, and ALTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	OKUR OnKure Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$12.53M	10.16	N/A	N/A	$0.55 per share	10.71
BHST BioHarvest Sciences	$30.19M	5.03	N/A	N/A	($0.26) per share	-35.54
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.38 per share	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$5.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
BHST BioHarvest Sciences	-$12.91M	-$0.70	N/A	N/A	N/A	-39.95%	-11,357.84%	-39.94%	N/A
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	N/A	-60.52%	-55.43%	11/6/2025 (Estimated)

Latest OKUR, BHST, HURA, and ALTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A
8/11/2025	Q2 2025	BHST BioHarvest Sciences	-$0.1075	-$0.15	-$0.0425	-$0.24	$8.53 million	$8.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.45	0.88	0.88
BHST BioHarvest Sciences	N/A	0.60	0.36
HURA TuHURA Biosciences	N/A	0.83	3.00
OKUR OnKure Therapeutics	N/A	11.13	11.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
BHST BioHarvest Sciences	N/A
HURA TuHURA Biosciences	0.62%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
BHST BioHarvest Sciences	N/A
HURA TuHURA Biosciences	0.20%
OKUR OnKure Therapeutics	17.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
HURA TuHURA Biosciences	N/A	50.05 million	43.59 million	N/A
OKUR OnKure Therapeutics	N/A	13.51 million	11.09 million	N/A

OKUR, BHST, HURA, and ALTS Headlines

Recent News About These Companies

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19 at 7:44 AM | finance.yahoo.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19 at 7:44 AM | finance.yahoo.com

Leerink Partnrs Has Positive Forecast for OKUR Q3 Earnings

August 16, 2025 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)

August 15, 2025 | theglobeandmail.com

OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)

August 12, 2025 | msn.com

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 12, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

OKUR OnKure Therapeutics, Inc.

June 12, 2025 | seekingalpha.com

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

June 3, 2025 | tipranks.com

Insider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of Stock

May 20, 2025 | insidertrades.com

OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 Shares

May 15, 2025 | insidertrades.com

Major Shareholder Sells Thousands of OnKure Therapeutics Shares!

May 14, 2025 | tipranks.com

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

May 9, 2025 | tipranks.com

OnKure increased R&D spending in 1Q with drug trials underway

May 7, 2025 | bizwest.comB

OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | finanznachrichten.de

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock News

April 30, 2025 | gurufocus.com

OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Charts

April 16, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, BHST, HURA, and ALTS Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$5.89 +0.41 (+7.48%)

Closing price 04:00 PM Eastern

Extended Trading

$5.88 -0.01 (-0.25%)

As of 07:59 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

BioHarvest Sciences NASDAQ:BHST

$9.24 +0.03 (+0.33%)

As of 03:53 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

TuHURA Biosciences NASDAQ:HURA

$2.98 -0.02 (-0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$2.92 -0.06 (-1.98%)

As of 07:07 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

OnKure Therapeutics NASDAQ:OKUR

$2.73 -0.01 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.73 0.00 (0.00%)

As of 04:10 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time